Translational changes: evidence for low-dose atropine and myopia control

Area of Science:

• Ophthalmology
• Optometry
• Pediatric Eye Care

Background:

• Myopia prevalence is rising globally, increasing risks of associated pathologies.
• Myopia control, focusing on preventing axial elongation, is now the standard of care for pediatric myopia.
• Pharmacological interventions, like atropine, are crucial for myopia management.

Purpose of the Study:

• To review the efficacy and safety of low-dose atropine (<0.1%) for pediatric myopia control.
• To provide an evidence-based approach for practitioners considering low-dose atropine.
• To compare low-dose atropine with higher concentrations regarding visual side effects.

Main Methods:

• Literature review of studies on atropine for myopia control.
• Analysis of publications and prescribing trends for low-dose atropine.
• Evaluation of clinical data on efficacy and adverse events.

Main Results:

• Low-dose atropine shows promising myopia control effects with reduced visual side effects compared to 1% atropine.
• There has been a significant increase in research and clinical use of low-dose atropine.
• Cycloplegia and mydriasis are significant side effects of 1% atropine, less so with low-dose formulations.

Conclusions:

• Low-dose atropine is an effective and well-tolerated option for pediatric myopia control.
• Practitioners should consider low-dose atropine as a viable strategy to prevent myopia progression.
• Further evidence-based research supports the integration of low-dose atropine into clinical practice.